Genitalia (e.g., Ovary, Uterus, Prostate, Testis, Etc.) Patents (Class 424/559)
-
Publication number: 20150079061Abstract: The invention provides a method of harvesting, processing and storing a plurality of proteins from a mammalian feto-placental unit. The method includes dissecting a mammalian uterus to harvest at least one component of the mammalian feto-placental unit; blast freezing the component; and storing the blast frozen component; wherein the blast frozen component includes the proteins. In one embodiment, the method includes lyophilizing the blast frozen component to remove at least some water from the blast frozen component thereby creating a freeze-dried form; and storing the lyophilized component; wherein the lyophilized component includes the proteins. The invention also provides a composition including proteins from at least one lyophilized, blast frozen component of a harvested mammalian feto-placental unit reconstituted with a fluid.Type: ApplicationFiled: July 14, 2014Publication date: March 19, 2015Inventors: Patrick J. Casey, Murray Hoare
-
Publication number: 20150079062Abstract: The invention provides a method of harvesting, processing and storing a plurality of proteins from a mammalian feto-placental unit. The method includes dissecting a mammalian uterus to harvest at least one component of the mammalian feto-placental unit; blast freezing the component; and storing the blast frozen component; wherein the blast frozen component includes the proteins. In one embodiment, the method includes lyophilizing the blast frozen component to remove at least some water from the blast frozen component thereby creating a freeze-dried form; and storing the lyophilized component; wherein the lyophilized component includes the proteins. The invention also provides a composition including proteins from at least one lyophilized, blast frozen component of a harvested mammalian feto-placental unit reconstituted with a fluid.Type: ApplicationFiled: November 24, 2014Publication date: March 19, 2015Inventors: Patrick J. Casey, Murray Hoare
-
Patent number: 8691276Abstract: Provided are methods for preparing gelled, solubilized extracellular matrix (ECM) compositions useful as cell growth scaffolds. Also provided are compositions prepared according to the methods as well as uses for the compositions. In one embodiment a device, such as a prosthesis, is provided which comprises an inorganic matrix into which the gelled, solubilized ECM is dispersed to facilitate in-growth of cells into the ECM and thus adaptation and/or attachment of the device to a patient.Type: GrantFiled: November 26, 2012Date of Patent: April 8, 2014Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Stephen F. Badylak, Donald Freytes
-
Patent number: 8361503Abstract: Provided are methods for preparing gelled, solubilized extracellular matrix (ECM) compositions useful as cell growth scaffolds. Also provided are compositions prepared according to the methods as well as uses for the compositions. In one embodiment a device, such as a prosthesis, is provided which comprises an inorganic matrix into which the gelled, solubilized ECM is dispersed to facilitate in-growth of cells into the ECM and thus adaptation and/or attachment of the device to a patient.Type: GrantFiled: February 29, 2008Date of Patent: January 29, 2013Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Stephen F. Badylak, Donald O. Freytes
-
Publication number: 20110002907Abstract: Methods and systems are provided for diagnosing male infertility relating to inadequate production of phosphatidic acid and are complementary to the routine tests, assessing sperm count, motility, viability, head morphology, and white blood cell count. Additional therapeutic methods, compositions and dosage forms are provided for treating male infertility that is related to inadequate production of phosphatidic acid. Such therapeutic approaches involve the use of phosphatidic acid or at least one of its precursors in the sperm intracellular signaling pathway.Type: ApplicationFiled: February 5, 2009Publication date: January 6, 2011Applicant: PEERION MEDICAL TECHNOLOGIES LTD.Inventor: Haim Breitbart
-
Publication number: 20100260815Abstract: The present invention provides devices and methods for concentrating a fluid and for treating a patient with the concentrated fluid. The concentrator apparatus includes a main housing (12) defining a separation chamber (14), a filter housing (48) containing a filter (46) comprising a filter element, a piping (44) for moving concentrated fluid from the separation chamber to the filter, and ports (32) for pressurizing the concentrated fluid past the filter element of the filter. The present invention also provides a variety of uses of concentrated body fluids, including autologous concentrated body fluid. The concentrated fluids can be used for example in surgical applications, including graft applications such as allograft, xenograft and autograft applications.Type: ApplicationFiled: June 20, 2008Publication date: October 14, 2010Applicant: Circle Biologics , LLCInventors: Matthew R. Kyle, Thomas Coull
-
Patent number: 7671027Abstract: The present invention concerns the use of an agonist of an hypothalamic hormone for the preparation of a pharmaceutical agent to support the luteal phase during infertility treatment of female mammals and more specifically of woman. According to this invention, the pharmaceutical agent is suitable to be used for supporting the luteal phase after a spontaneous ovulation or after stimulation of follicular growth, trigger of final follicular maturation and ovulation with one or several additional agents.Type: GrantFiled: December 29, 2003Date of Patent: March 2, 2010Assignee: PregLem S.A.Inventor: Ernest Loumaye
-
Publication number: 20080260831Abstract: Provided are methods for preparing gelled, solubilized extracellular matrix (ECM) compositions useful as cell growth scaffolds. Also provided are compositions prepared according to the methods as well as uses for the compositions. In one embodiment a device, such as a prosthesis, is provided which comprises an inorganic matrix into which the gelled, solubilized ECM is dispersed to facilitate in-growth of cells into the ECM and thus adaptation and/or attachment of the device to a patient.Type: ApplicationFiled: February 29, 2008Publication date: October 23, 2008Inventors: Stephen F. Badylak, Donald O. Freytes
-
Publication number: 20080152683Abstract: A new application of a component extracted from a Salmonidae fish ovarian membrane is provided. A cosmetic product of the present invention contains a Salmonidae fish ovarian membrane or a component obtained by treating the ovarian membrane with a protease. The cosmetic product can be used as any one of (1) a cosmetic product for inhibiting skin allergy symptoms; (2) a cosmetic product for improving skin conditions for the lightening of pigmentation and freckles, the reduction of skin dullness, and the whitening of skin; (3) a cosmetic product for improving darkened pores; and (4) a cosmetic product for increasing the amount of sebum on skin. In the cosmetic products for improving darkened pores and for increasing the amount of sebum on skin, the component obtained by treating The Salmonidae fish ovarian membrane with a protease is preferably grains having an average grain size of 200 to 1400 nm.Type: ApplicationFiled: December 21, 2007Publication date: June 26, 2008Applicant: NIPPON BARRIER FREE CO., LTD.Inventor: Tadashi Eto
-
Patent number: 6916492Abstract: The present invention discloses the process of extraction, purification and characterization of a natural eco-friendly nontoxic cell permeant multiple fluorescent protein dye from a non bioluminescent marine echinoderm Holothuria scabra, compositions containing the dye and various applications of the dye.Type: GrantFiled: March 28, 2002Date of Patent: July 12, 2005Assignee: Council of Scientific & Industrial ResearchInventors: Usha Goswami, Anutosh Ganguly
-
Patent number: 6908627Abstract: Conditioned media compositions having valuable biological activity are obtained from cultures of immune cells from elasmobranch fishes. Methods are provided for producing the conditioned media compositions. Conditioned media obtained using epigonal cells from bonnethead sharks (Sphyrna tiburo) and lemon sharks (Negaprion brevirostris) demonstrate strong anti-tumor activities. The conditioned media compositions can be used for treating tumor proliferation and in immunosuppressive therapy.Type: GrantFiled: June 14, 2002Date of Patent: June 21, 2005Assignee: Mote Marine LaboratoryInventors: Catherine Walsh, Carl Luer
-
Patent number: 6689391Abstract: The present invention discloses a process of extraction, purification and characterization of a non-polar fluorescent dye from a marine echinoderm Holothuria scabra, compositions containing the dye and various applications of the dye, said dye is a natural, cell permeant, nontoxic and environmentally friendly non-polar fluorescent dye.Type: GrantFiled: March 28, 2002Date of Patent: February 10, 2004Assignee: Council of Scientific & Industrial ResearchInventors: Usha Goswami, Anutosh Ganguly
-
Patent number: 6656969Abstract: The invention provides for methods of monitoring the proliferation of cultured prostate cancer cells in the presence of omega-3 fatty acids, methods of treating an individual with prostate cancer or at risk of developing prostate cancer, and methods of reducing the risk of recurrence of prostate cancer in an individual who had previously been treated for prostate cancer. Methods of the invention further include treating an individual with benign prostatic hyperplasia (BPH) with omega-3 fatty acids as well as methods of screening for compounds that inhibit the proliferation of prostate cancer cells. The invention provides for compositions and articles of manufacture containing omega-3 fatty acids in particular formulations, and omega-3 fatty acids with a second compound that also exerts an effect on the androgen receptor.Type: GrantFiled: September 20, 2001Date of Patent: December 2, 2003Assignee: Mayo Foundation for Medical Education and ResearchInventor: Charles Young
-
Patent number: 6562621Abstract: A method of using fish ovarian fluid for culture and preservation of mammalian cells includes obtaining ovarian fluid from a fish, and culturing mammalian cells in media including a commercially defined medium and a nutrient medium, wherein the nutrient medium includes the fish ovarian fluid. The cells may initially be cultured in a commercial medium and a conventional nutrient medium prior to culture in the fish ovarian fluid. Living cells may also be preserved by obtaining ovarian fluid from a fish, isolating the living cells, and adding the fish ovarian fluid to the living cells.Type: GrantFiled: October 27, 2000Date of Patent: May 13, 2003Assignee: Sea Run Holdings, Inc.Inventors: Evelyn S. Sawyer, Philip J. Sawyer, Paul A. Janmey
-
Publication number: 20030021851Abstract: The present invention discloses a process of extraction, purification and characterization of a non-polar fluorescent dye from a marine echinoderm Holothuria scabra, compositions containing the dye and various applications of the dye, said dye is a natural, cell permeant, nontoxic and environmentally friendly non-polar fluorescent dye.Type: ApplicationFiled: March 28, 2002Publication date: January 30, 2003Inventors: Usha Goswami, Anutosh Ganguly
-
Publication number: 20020187202Abstract: The present invention discloses the process of extraction, purification and characterization of a natural eco-friendly nontoxic cell permeant multiple fluorescent protein dye from a non bioluminescent marine echinoderm Holothuria scabra, compositions containing the dye and various applications of the dye.Type: ApplicationFiled: March 28, 2002Publication date: December 12, 2002Inventors: Usha Goswami, Anutosh Ganguly
-
Patent number: 6306823Abstract: The subject invention relates to a new forward motility protein isolated from goat epididymal plasma and a process for the isolation of the said epididymal forward motility protein useful as a fertility promoter/blocker comprising subjecting goat epididymal plasma to multiple fractionations till purification to obtain purified new epididymal forward motility protein by the chromatographic method.Type: GrantFiled: July 27, 1999Date of Patent: October 23, 2001Assignee: Council of Scientific & Industrial ResearchInventors: Gopal Chandra Majumder, Bijay Shankar Jaiswal
-
Patent number: 6054142Abstract: A biocompatible cell device having an internal foam scaffold to provide a growth surface for encapsulated cells which produce a biologically active molecule.Type: GrantFiled: August 1, 1996Date of Patent: April 25, 2000Assignee: Cyto Therapeutics, Inc.Inventors: Rebecca Li, Tyrone F. Hazlett
-
Patent number: 5997908Abstract: A composition of matter comprising crystalline zinc chelated with animal prostate extract provides a convenient source of both fatty acids and zinc for dietary and therapeutic purposes. The pharmaceutical composition is useful for the treatment of diabetes.Type: GrantFiled: March 24, 1997Date of Patent: December 7, 1999Inventor: Moon K. Song
-
Patent number: 5925362Abstract: Vaccines capable of eliciting an immune antitumor response for prostate tumors are disclosed. The active ingredient in such vaccines is selected from the group consisting of human PSA and expression system capable of generating in situ human PSA.Type: GrantFiled: August 10, 1994Date of Patent: July 20, 1999Assignee: Jenner TechnologiesInventors: Lynn E. Spitler, Anthony E. Maida, III
-
Patent number: 5830460Abstract: A method of producing a sustained localized brain immunosuppressive effect in localized tissues is achieved by transplanting Sertoli cells proximate to the brain tissue.Type: GrantFiled: March 13, 1995Date of Patent: November 3, 1998Assignee: University of South FloridaInventors: Paul R. Sanberg, Don F. Cameron, Cesario V. Borlongan, Richard Heller
-
Patent number: 5736141Abstract: A vaccine for the immunocontraception of mammals is described. The vaccine consists of zona pellucida antigens and an adjuvant encapsulated in a liposome delivery system. The liposome delivery system allows for the slow release of antigen resulting in a prolonged immune response. In particular, after a single injection of the vaccine, levels of anti-zona pellucida antibodies were detected for up to 22 months in seals. Thus, the vaccine according to the present invention is effective after a single dose and is therefore very useful in immunocontraceptive protocols.Type: GrantFiled: October 30, 1996Date of Patent: April 7, 1998Assignee: Dalhousie UniversityInventors: Robert Brown, Michael Mezei, Bill Pohajdak, Warwick Charles Kimmins
-
Patent number: 5721348Abstract: The disclosure relates to isolated DNA encoding all or a portion of a surface protein present in sperm of a mammal. This surface protein of sperm is essential for fertilization in the mammal. Preferably, the sperm surface protein is the PH-20 protein.Type: GrantFiled: October 21, 1991Date of Patent: February 24, 1998Assignee: University of ConnecticutInventors: Paul Primakoff, Diana G. Myles
-
Patent number: 5708157Abstract: Novel polynucleotides and the proteins encoded thereby are disclosed.Type: GrantFiled: July 26, 1996Date of Patent: January 13, 1998Assignee: Genetics Institute, Inc.Inventors: Kenneth Jacobs, John M. McCoy, Edward R. LaVallie, Lisa A. Racie, David Merberg, Maurice Treacy, Cheryl Evans, Vikki Spaulding
-
Patent number: 5569812Abstract: A nude mouse model for human neoplastic disease having histologically intact human neoplastic tissue transplanted onto an organ of the mouse which corresponds to the human organ from which the tissue is obtained.Type: GrantFiled: June 2, 1995Date of Patent: October 29, 1996Assignee: Anticancer IncorporatedInventors: Ann Monosov, Xinyu Fu
-
Patent number: 5563059Abstract: A method is provided for increasing the fertilization potential of oocytes comprising culturing oocytes in vitro with an effective amount of inhibin, activin, or a combination of inhibin and activin. Preferably the oocytes being cultured are immature. After the culturing step, the oocytes can be fertilized. The oocytes are suitably cryopreserved and thawed before the culturing step.Type: GrantFiled: February 23, 1993Date of Patent: October 8, 1996Assignees: Genentech, Inc., Medical Research Foundation of OregonInventors: Baha M. Alak, Richard L. Stouffer, Don P. Wolf, Teresa K. Woodruff
-
Patent number: 5560935Abstract: The present invention provides a physiologically active substance which inhibits plasma kallikrein production, improves peripheral blood flow, and exhibits analgesic, antiinflammatory and antiallergic action. The physiologically active substance of the present invention is prepared by activating various animals or animal tissues by means of inoculation with virus or tumor cells which act as a stressor, and then extracting the effective factor from the activated tissues. The substance exhibits a pharmacological action of inhibiting activity for production of plasma kallikrein and recovering and normalizing abnormal functions which are associated with the diseased state. The physiologically active substance and pharmaceutical compositions of the present invention exhibit excellent regulating activity for biofunctions. They provide recovery and normalization of abnormal functions in living organisms in various diseased states.Type: GrantFiled: September 27, 1994Date of Patent: October 1, 1996Assignee: Nippon Zoki Pharmaceutical Co., Ltd.Inventors: Jin-emon Konishi, Giichi Hamada
-
Patent number: 5484768Abstract: A method for the treatment of infertility associated with undescended testes in male animals is disclosed. Also disclosed is a method for effecting testicular germ cell maturation.These methods involve administering to a subject in need of such treatment a therapeutically effective amount of Mullerian inhibiting substance (MIS) or an analogue thereof having MIS activity.MIS may be administered to a subject shortly after treatment to effect testes descent and/or prior to testes descent.Type: GrantFiled: March 8, 1993Date of Patent: January 16, 1996Assignee: The University of MelbourneInventors: Patricia K. Donahue, John M. Hutson
-
Patent number: 5411748Abstract: A composition of matter comprising zinc and an extract of animal prostatic tissue provides a convenient source of both fatty acids and zinc for dietary and therapeutic purposes. The pharmaceutical composition is useful for the treatment of diabetes.Type: GrantFiled: January 7, 1994Date of Patent: May 2, 1995Inventor: Moon K. Song
-
Patent number: 5277917Abstract: Herein described is an ovarian cancer activating factor that has been isolated from ovarian cancer ascites fluid. The factor may be utilized in its isolated form in a screening program aimed at identifying inhibitors of factor-mediated ovarian cancer activation, or as a growth supplement useful for culturing ovarian and other cancer cell lines.Type: GrantFiled: April 2, 1993Date of Patent: January 11, 1994Assignee: Allelix Biopharmaceuticals Inc.Inventors: Yan Xu, Anne E. Goodbody
-
Patent number: 5198216Abstract: A composition for enhancing the performance of animals, such as horses or dogs, is composed of adrenal and pituitary raw tissue concentrates, vitamin C, bioflavonoid complex, pantothenic acid, methionine, choline, vitamin B1, vitamin B2, vitamin B6, niacinamide, magnesium, vitamin B12, folic acid and organic iodine. The composition is adapted to be orally administered to an animal, is composed of all natural substances, and the relative proportions of the components are approximately:at least 40 parts adrenal raw tissue concentrate toat least 2 parts pituitary raw tissue concentrate to30-60 parts vitamin C to20-30 parts magnesium to10-20 parts of each of pantothenic acid, methionine and choline to8-15 parts of each of niacinamide and bioflavonoid complex to1-5 parts of each of vitamins B1, B2 and B6 to0.1-1 parts organic iodine to0.05-0.5 parts folic acid.Type: GrantFiled: July 30, 1990Date of Patent: March 30, 1993Assignee: Daliff CorporationInventor: David M. McGee
-
Patent number: 5102868Abstract: A method is provided for inhibiting the maturation of follicles in the ovary of a femal mammal comprising administering to the ovary of the mammal an effective amount of activin. This method is particularly effective in treating polycystic ovarian disease.Type: GrantFiled: January 8, 1990Date of Patent: April 7, 1992Assignee: Genentech, Inc.Inventors: Teresa K. Woodruff, Jennie P. Mather
-
Patent number: 5102867Abstract: A method of treating a patient exhibiting a neoplasm is provided comprising administering a therapeutically effective dose of Follicle Regulatory Protein (FRP), or a polypeptide analog thereof. The method may be used both pre- and post-operatively.Type: GrantFiled: July 14, 1989Date of Patent: April 7, 1992Assignee: Decatur-FRP/PartnersInventor: Donald L. Morton
-
Patent number: 5057324Abstract: A physiologically active substance is extracted from infected tissues inoculated with a poxvirus. The novel substance of the present invention has inhibitory action against the formation of kallikrein, thus is useful as drugs such as antiinflammatory, analgesic and antiallergic agents.Type: GrantFiled: July 20, 1988Date of Patent: October 15, 1991Assignee: Nippon Zoki Pharmaceutical Co., Ltd.Inventors: Yoji Shibayama, Yoshio Toyomaki
-
Patent number: 5057497Abstract: Absorption of Tissue Respiration Factor (TRF) into the gingival tissues is materially enhanced when it is formulated as a non-astringent hydrophilic pharmaceutical composition containing penetration promoting substances which are both hydrophilic and lipophilic. Additionally, a highly efficient means for effecting absorption of TRF into the gingival tissues is to utilize liposomes as carriers for the TRF in a non-astringent pharmaceutical composition.Type: GrantFiled: July 13, 1989Date of Patent: October 15, 1991Assignee: Calam & Associates, Inc.Inventors: Henry D. Calam, Hans A. Schaeffer
-
Patent number: 5011687Abstract: Purified Mullerian inhibiting substance (MIS) is obtained from testicular tissue by extraction, density gradient sedimentation and chromatography. The purified MIS has selective activity for inhibiting the growth of human ovarian cancer cells.Type: GrantFiled: October 29, 1985Date of Patent: April 30, 1991Assignee: The General Hospital CorporationInventors: Patricia K. Donahoe, David A. Swann
-
Patent number: 4996297Abstract: The invention relates to antigenic preparations useful for inducing the production of antibodies in an individual which will bind to epitopes on zona pellucida. Also disclosed are immunogenic compositions and methods for immunizing an individual to enable the production of antibodies to zona pellucida antigens. Also disclosed are the use of these recombinant molecules and monoclonal antibodies thereto for immunocontraception or sterilization.Type: GrantFiled: October 7, 1987Date of Patent: February 26, 1991Assignee: Zonagen, Inc.Inventor: Bonita S. Dunbar
-
Patent number: 4985254Abstract: The present invention relates to physiologically active substances extracted from infected tissues inoculated with a poxvirus. The substances of the present invention have excellent actions to improve blood flow and recover functions of diseased tissues, thus are useful as drugs for various diseases caused by blood flow disorders.Type: GrantFiled: November 3, 1988Date of Patent: January 15, 1991Assignee: Nippon Zoki Pharmaceutical Co., Ltd.Inventor: Jin-emon Konishi
-
Patent number: 4962187Abstract: A purified common antigen for colorectal and mucinous ovarian cancer (COTA) is provided which is antigenically distinct from CSAp, CEA and Ca 19-9. The COTA antigen is useful for producing a COTA antibody which is nonreactive with CSAp, CEA or Ca 19-9.Type: GrantFiled: November 21, 1986Date of Patent: October 9, 1990Assignee: Cota BiotechInventor: Keshab D. Pant
-
Patent number: RE37224Abstract: A vaccine for the immunocontraception of mammals is described. The vaccine consists of zona pellucida antigens and an adjuvant encapsulated in a liposome delivery system. The liposome delivery system allows for the slow release of antigen resulting in a prolonged immune response. In particular, after a single injection of the vaccine, levels of anti-zona pellucida antibodies were detected for up to 22 months in seals. Thus, the vaccine according to the present invention is effective after a single dose and is therefore very useful in immunocontraceptive protocols.Type: GrantFiled: July 23, 1998Date of Patent: June 12, 2001Assignee: Dalhousie UniversityInventors: Robert Brown, Michael Mezei, Bill Pohajdak, Warwick Charles Kimmins
-
Patent number: RE39337Abstract: A nude mouse model for human neoplastic diseases having histologically intact human neoplastic tissue transplanted onto an organ of the mouse which corresponds to the human organ from which the tissue is obtained.Type: GrantFiled: February 13, 1998Date of Patent: October 10, 2006Assignee: Anticancer, Inc.Inventors: Ann Monosov, Xinyu Fu